Related Experiment Video

Updated: May 26, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Zalutumumab in head and neck cancer

Ulrike Schick1, Dorothy M Gujral, Tom M Richards

  • 1Royal Marsden Hospital, Clinical Oncology, Head and Neck Unit, Fulham Road, London, SW3 6JJ , UK.

Expert Opinion on Biological Therapy
|December 17, 2011
PubMed
Abstract

Insights

Zalutumumab, a fully human antibody targeting EGFR, shows promise for head and neck cancer treatment. It demonstrates acceptable toxicity and encouraging survival results in clinical trials.

Area of Science:

  • Oncology
  • Immunotherapy
  • Pharmacology

Background:

  • Over 90% of head and neck cancers exhibit epidermal growth factor receptor (EGFR) overexpression, correlating with advanced disease and poor prognosis.
  • Targeting the EGFR pathway is a key strategy in head and neck cancer treatment.
  • Zalutumumab is a fully human IgG1k antibody designed for high-affinity EGFR inhibition.

Purpose of the Study:

  • To review the mechanism of action, efficacy, and safety of zalutumumab in head and neck cancer.
  • To evaluate zalutumumab as a potential therapeutic option for patients with advanced disease.

Main Methods:

  • Review of mechanism of action, efficacy, and safety data for zalutumumab.
  • Analysis of data from Phase I, II, and III clinical trials.

Main Results:

  • Zalutumumab exhibits acceptable toxicity, with rash as the most common adverse event.
  • The fully human nature of zalutumumab suggests a low risk of hypersensitivity.
  • Phase I/II trials indicate zalutumumab is a promising agent for locally advanced head and neck cancer.
  • Phase III trials have shown encouraging survival outcomes compared to best supportive care.

Conclusions:

  • Zalutumumab's safety profile makes it suitable for heavily pretreated patients or those with poor performance status.
  • Antibody-dependent cellular cytotoxicity may contribute to zalutumumab's efficacy.
  • Further Phase III trial results are anticipated to clarify zalutumumab's role in treatment.
  • Clinical development was suspended in June 2011 pending a partnership.

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Translationally-Relevant Tumor Resection Model for Murine Preclinical Models of Oral Squamous Cell Carcinoma07:59

Translationally-Relevant Tumor Resection Model for Murine Preclinical Models of Oral Squamous Cell Carcinoma

Published on: April 3, 2026

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.